Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.41M | -1.72M | -1.58M | -2.97M | -2.66M |
| Total Depreciation and Amortization | 3.20K | 3.30K | 44.80K | 134.70K | 33.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 799.50K | 457.60K | 707.30K | 334.90K | 427.70K |
| Change in Net Operating Assets | -4.40K | 488.30K | 708.00K | 987.20K | -503.60K |
| Cash from Operations | -1.61M | -771.80K | -123.30K | -1.51M | -2.70M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 14.50K | 3.50K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 14.50K | 3.50K | -- |
| Total Debt Issued | 1.49M | -- | 90.50K | 173.70K | 4.67M |
| Total Debt Repaid | -4.00M | -- | -6.80K | -20.30K | -43.30K |
| Issuance of Common Stock | 5.28M | 1.28M | 266.90K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -76.60K | 76.60K | -18.20K | 0.00 | 0.00 |
| Cash from Financing | 1.96M | 1.00M | 239.50K | 111.70K | 3.26M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 348.60K | 229.40K | 130.70K | -1.39M | 555.90K |